FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200219632> ?p ?o ?g. }

• W4200219632 endingPage "S534" @default.
• W4200219632 startingPage "S534" @default.
• W4200219632 abstract "Abstract Background Limited data exist among women living with HIV who become pregnant while exposed to long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV). We report outcomes in pregnant participants and LA pharmacokinetic (PK) tail data in pregnant women exposed to CAB+RPV with live births. Methods Women of reproductive potential exposed to ≥ 1 dose of CAB+RPV (oral/LA) from ViiV-sponsored Phase 2/3/3b clinical treatment studies and the compassionate use program were included in this analysis and pregnancies identified. Per protocol, upon identification of pregnancy, CAB+RPV was discontinued and an alternative regimen initiated, with continued quarterly PK sampling for 52 weeks post last injection during long-term safety follow-up (LTFU). Descriptive characteristics of pregnant women and birth outcomes and available CAB and RPV PK during pregnancy for those with live births are summarized. Results As of March 31, 2021, 26/325 women of reproductive potential (age 18–49 years) became pregnant while exposed to CAB+RPV (5 oral, 21 LA [including 3 following LA discontinuation]). There were 11 live births (1 oral, 10 LA), of which 10 had no reported congenital abnormalities and 1 had reported congenital ptosis, in a pre-term infant with intrauterine growth restriction. There were 9 elective terminations and 6 miscarriages (5 in first 9 weeks of gestation). Ten women exposed to intramuscular CAB+RPV LA became pregnant with subsequent live birth outcomes, including 3 infants conceived during the PK tail in LTFU. All women were virologically suppressed at time of pregnancy identification. In women becoming pregnant on LA dosing, plasma CAB and RPV concentrations during pregnancy were within the range of expected concentrations in non-pregnant women. Two of 10 women with live births exposed to CAB+RPV LA continued LA therapy during pregnancy (compassionate use program participants). Conclusion Pregnancy outcomes in women exposed to CAB+RPV at conception are consistent with earlier findings. There was 1 reported congenital anomaly among 11 live births. CAB and RPV PK tail in pregnancy was within the expected range for non-pregnant women. Ongoing monitoring of birth defects within the antiretroviral pregnancy registry and pregnancy surveillance within the treatment program continues. Disclosures Parul Patel, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Susan L. Ford, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Mark Baker, PhD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Claudia Meyer, MBChB, MRCP, MSc, FRCPath, DTM&H, GlaxoSmithKline (Employee, Shareholder) Louise Garside, PhD, GlaxoSmithKline (Employee) Ronald D’Amico, DO, MSc, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Rodica Van Solingen-Ristea, MD, Janssen Research and Development (Employee)ViiV Healthcare (Employee) Herta Crauwels, PhD, Janssen (Employee) Joseph Polli, PhD, FAAPS, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Ciara Seal, BS, GlaxoSmithKline (Employee, Shareholder) Shanker Thiagarajah, MB ChB, GlaxoSmithKline (Employee, Shareholder) Eileen Birmingham, MD, MPH, Janssen Research and Development (Employee, Shareholder) William Spreen, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Bryan Baugh, MD, Janssen, Johnson & Johnson (Employee, Shareholder) Matthew Bosse, DO, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Vani Vannappagari, MBBS, MPH, PhD, ViiV Healthcare Limited (Employee)" @default.
• W4200219632 created "2021-12-31" @default.
• W4200219632 creator A5003069757 @default.
• W4200219632 creator A5009272615 @default.
• W4200219632 creator A5011202454 @default.
• W4200219632 creator A5019702306 @default.
• W4200219632 creator A5031429222 @default.
• W4200219632 creator A5033195921 @default.
• W4200219632 creator A5033567205 @default.
• W4200219632 creator A5044001938 @default.
• W4200219632 creator A5046228013 @default.
• W4200219632 creator A5048320845 @default.
• W4200219632 creator A5050457597 @default.
• W4200219632 creator A5057748120 @default.
• W4200219632 creator A5058435210 @default.
• W4200219632 creator A5061545727 @default.
• W4200219632 creator A5075216573 @default.
• W4200219632 creator A5087039800 @default.
• W4200219632 date "2021-11-01" @default.
• W4200219632 modified "2023-10-18" @default.
• W4200219632 title "885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials" @default.
• W4200219632 doi "https://doi.org/10.1093/ofid/ofab466.1080" @default.
• W4200219632 hasPublicationYear "2021" @default.
• W4200219632 type Work @default.
• W4200219632 citedByCount "4" @default.
• W4200219632 countsByYear W42002196322022 @default.
• W4200219632 countsByYear W42002196322023 @default.
• W4200219632 crossrefType "journal-article" @default.
• W4200219632 hasAuthorship W4200219632A5003069757 @default.
• W4200219632 hasAuthorship W4200219632A5009272615 @default.
• W4200219632 hasAuthorship W4200219632A5011202454 @default.
• W4200219632 hasAuthorship W4200219632A5019702306 @default.
• W4200219632 hasAuthorship W4200219632A5031429222 @default.
• W4200219632 hasAuthorship W4200219632A5033195921 @default.
• W4200219632 hasAuthorship W4200219632A5033567205 @default.
• W4200219632 hasAuthorship W4200219632A5044001938 @default.
• W4200219632 hasAuthorship W4200219632A5046228013 @default.
• W4200219632 hasAuthorship W4200219632A5048320845 @default.
• W4200219632 hasAuthorship W4200219632A5050457597 @default.
• W4200219632 hasAuthorship W4200219632A5057748120 @default.
• W4200219632 hasAuthorship W4200219632A5058435210 @default.
• W4200219632 hasAuthorship W4200219632A5061545727 @default.
• W4200219632 hasAuthorship W4200219632A5075216573 @default.
• W4200219632 hasAuthorship W4200219632A5087039800 @default.
• W4200219632 hasBestOaLocation W42002196321 @default.
• W4200219632 hasConcept C131872663 @default.
• W4200219632 hasConcept C141071460 @default.
• W4200219632 hasConcept C142462285 @default.
• W4200219632 hasConcept C2778279030 @default.
• W4200219632 hasConcept C2778715236 @default.
• W4200219632 hasConcept C2778723075 @default.
• W4200219632 hasConcept C2779234561 @default.
• W4200219632 hasConcept C2779502633 @default.
• W4200219632 hasConcept C2781413609 @default.
• W4200219632 hasConcept C29456083 @default.
• W4200219632 hasConcept C2993143319 @default.
• W4200219632 hasConcept C3013748606 @default.
• W4200219632 hasConcept C512399662 @default.
• W4200219632 hasConcept C54355233 @default.
• W4200219632 hasConcept C71924100 @default.
• W4200219632 hasConcept C86803240 @default.
• W4200219632 hasConceptScore W4200219632C131872663 @default.
• W4200219632 hasConceptScore W4200219632C141071460 @default.
• W4200219632 hasConceptScore W4200219632C142462285 @default.
• W4200219632 hasConceptScore W4200219632C2778279030 @default.
• W4200219632 hasConceptScore W4200219632C2778715236 @default.
• W4200219632 hasConceptScore W4200219632C2778723075 @default.
• W4200219632 hasConceptScore W4200219632C2779234561 @default.
• W4200219632 hasConceptScore W4200219632C2779502633 @default.
• W4200219632 hasConceptScore W4200219632C2781413609 @default.
• W4200219632 hasConceptScore W4200219632C29456083 @default.
• W4200219632 hasConceptScore W4200219632C2993143319 @default.
• W4200219632 hasConceptScore W4200219632C3013748606 @default.
• W4200219632 hasConceptScore W4200219632C512399662 @default.
• W4200219632 hasConceptScore W4200219632C54355233 @default.
• W4200219632 hasConceptScore W4200219632C71924100 @default.
• W4200219632 hasConceptScore W4200219632C86803240 @default.
• W4200219632 hasIssue "Supplement_1" @default.
• W4200219632 hasLocation W42002196321 @default.
• W4200219632 hasLocation W42002196322 @default.
• W4200219632 hasOpenAccess W4200219632 @default.
• W4200219632 hasPrimaryLocation W42002196321 @default.
• W4200219632 hasRelatedWork W2810063204 @default.
• W4200219632 hasRelatedWork W2900399017 @default.
• W4200219632 hasRelatedWork W2910368971 @default.
• W4200219632 hasRelatedWork W2969804444 @default.
• W4200219632 hasRelatedWork W2981427637 @default.
• W4200219632 hasRelatedWork W3143772066 @default.
• W4200219632 hasRelatedWork W3207788568 @default.
• W4200219632 hasRelatedWork W4210325848 @default.
• W4200219632 hasRelatedWork W4247604720 @default.
• W4200219632 hasRelatedWork W4280582041 @default.
• W4200219632 hasVolume "8" @default.
• W4200219632 isParatext "false" @default.
• W4200219632 isRetracted "false" @default.
• W4200219632 workType "article" @default.